# Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/ABUS/arbutus-reports-first-quarter-2025-financial-results-and-provides-corporate-update
Ticker: ABUS
Company: Arbutus
Source: Arbutus
Published: 2025-05-14 11:30 EST
Original Source URL: https://investor.arbutusbio.com
## Summary

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no  interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b

## Article Body
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no  interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b
## Recent Company News
- 2026-07-16 11:30 EST — [Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders](https://biopharmsignal.com/news/ABUS/arbutus-initiates-international-patent-infringement-enforcement-actions-against--c6198417) — Source: Arbutus
- 2026-05-13 11:30 EST — [Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ABUS/arbutus-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Arbutus
- 2026-04-15 11:30 EST — [Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B](https://biopharmsignal.com/news/ABUS/arbutus-receives-u-s-fda-fast-track-designation-for-imdusiran-for-the-treatment-of-chronic-hepatitis-b) — Source: Arbutus
- 2026-03-23 11:30 EST — [Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ABUS/arbutus-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update) — Source: Arbutus
- 2026-03-03 21:15 EST — [Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna](https://biopharmsignal.com/news/ABUS/genevant-sciences-and-arbutus-biopharma-announce-2-25-billion-global-settlement-with-moderna) — Source: Arbutus
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)